Astragaloside IV attenuates Toll-like receptor 4 expression via NF-¦ÊB pathway under high glucose condition in mesenchymal stem cells

详细信息    查看全文

• 作者：Mincai Li^a ; ^b ; ^{mincaili01@gmail.com} ; Liangzu Yu^a ; Tonghui She^a ; ^b ; Yapin Gan^b ; Fuxin Liu^b ; Zhengwu Hu^b ; Yongbin Chen^b ; Suqin Li^a ; ^b ; Hongli Xia^c
• 关键词：Astragaloside IV ; Toll-like receptor 4 ; NF-¦ÊB pathway ; Bone mesenchymal stem cell ; Diabetes
• 刊名：European Journal of Pharmacology
• 出版年：2012
• 出版时间：5 December, 2012
• 年：2012
• 卷：696
• 期：1-3
• 页码：203-209
• 全文大小：395 K

文摘

Diabetic hyperglycemia causes a variety of pathological changes. Astragaloside IV (AS-IV) was widely used for the treatment of cardiovascular diseases in China. The aim of this study was to determine the effect of AS-IV on bone marrow mesenchymal stem cells (MSCs) and the underlying mechanism in diabetes. We used reverse transcription polymerase chain reaction and western blotting to determine the expression of Toll-like receptor 4 (TLR4), matrix metalloproteinase-2 (MMP-2) and NF-¦ÊB p65 in MSCs under high glucose (HG) with or without pretreatment with AS-IV. The surface expression of TLR4 was checked by flow cytometry and the expression of TNF-¦Á and MCP-1 were detected by ELISA in diabetes patients treated with AS-IV. AS-IV promoted the proliferation of MSCs and attenuated the increased expression of TLR4 induced by HG. In addition, AS-IV decreased the HG-induced translocation of NF-¦ÊB p65 and increased the MMP-2 expression in MSCs. AS-IV decreased the TLR4, TNF-¦Á and MCP-1 expression in patients. Collectively,our data revealed that AS-IV attenuated TLR4 expression through the NF-¦ÊB signaling pathway in MSCs.